Isik AT, et al. - Researchers analyzed longitudinal (without a control group) and cohort (with a control group) studies reporting cardiovascular (CV) impacts of acetylcholinesterase inhibitors (AChEIs) in individuals with dementia. They excluded randomized controlled trials. They found that data showed the association of AChEIs with a significantly greater incidence of hypertension and bradycardia. Decrease in heart rate and an increase in PR interval from baseline were also reported in those taking AChEIs. Overall, a possible association of AChEI therapy with negative chronotropic and hypertensive impacts, but also with lower risk of CV events was seen.